caa a22 4500 445344296 CHVBK 20180317142824.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s00406-010-0142-x doi (NATIONALLICENCE)springer-10.1007/s00406-010-0142-x Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone [Elektronische Daten] [Marc De Hert, Aurélia Mittoux, Yuan He, Joseph Peuskens] The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. The short- and long-term metabolic safety of sertindole was compared to that of risperidone in a subset of patients enrolled in the sertindole cohort prospective (SCoP) study, an open randomized study. In 261 randomized patients, there were moderate increases in mean weight, BMI, and waist circumference during treatment with either sertindole or risperidone; after 12weeks, the increase in weight was 1.3 and 1.1kg, respectively, and after 36weeks, it was 2.2 and 2.0kg, respectively. From baseline to last assessment (up to 60weeks), weight gains of 1.8 and 1.7kg for sertindole and risperidone, respectively, were observed. Similar proportions of patients (sertindole: 17% versus risperidone: 16%) had weight increases ≥7% from baseline to last assessment. The mean changes from baseline in triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, plasma glucose and blood pressure were small and not clinically relevant in both treatment groups. No patient in either of the groups developed type 2 diabetes during the study. At last assessment, the prevalence of metabolic syndrome (International Diabetes Federation) was 17% in the sertindole group and 26% in the risperidone group and the incidence of metabolic syndrome was 7% in the sertindole group and 10% in the risperidone group. Treatment with either sertindole or risperidone did not appear to be associated with an increased comparative risk of developing metabolic syndrome. In general, the metabolic effects of sertindole and risperidone were similar. Springer-Verlag, 2010 Metabolic syndrome nationallicence Risperidone nationallicence Sertindole nationallicence Side effects nationallicence Schizophrenia nationallicence De Hert Marc University Psychiatric Center Catholic University Leuven, UPC KUL campus Kortenberg, Leuvensesteenweg 517, 3070, Kortenberg, Belgium aut Mittoux Aurélia H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, Denmark aut He Yuan H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, Denmark aut Peuskens Joseph University Psychiatric Center Catholic University Leuven, UPC KUL campus Kortenberg, Leuvensesteenweg 517, 3070, Kortenberg, Belgium aut European Archives of Psychiatry and Clinical Neuroscience Springer-Verlag 261/4(2011-06-01), 231-239 0940-1334 261:4<231 2011 261 406 https://doi.org/10.1007/s00406-010-0142-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00406-010-0142-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- De Hert Marc University Psychiatric Center Catholic University Leuven, UPC KUL campus Kortenberg, Leuvensesteenweg 517, 3070, Kortenberg, Belgium aut NATIONALLICENCE 700 1- Mittoux Aurélia H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, Denmark aut NATIONALLICENCE 700 1- He Yuan H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Peuskens Joseph University Psychiatric Center Catholic University Leuven, UPC KUL campus Kortenberg, Leuvensesteenweg 517, 3070, Kortenberg, Belgium aut NATIONALLICENCE 773 0- European Archives of Psychiatry and Clinical Neuroscience Springer-Verlag 261/4(2011-06-01), 231-239 0940-1334 261:4<231 2011 261 406 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer